ECSP055705A - (tiazol-2-il)-amida o sulfonamida substituida como activadores de glicocinasa utiles en el tratamiento de diabetes de tipo 2 - Google Patents

(tiazol-2-il)-amida o sulfonamida substituida como activadores de glicocinasa utiles en el tratamiento de diabetes de tipo 2

Info

Publication number
ECSP055705A
ECSP055705A EC2005005705A ECSP055705A ECSP055705A EC SP055705 A ECSP055705 A EC SP055705A EC 2005005705 A EC2005005705 A EC 2005005705A EC SP055705 A ECSP055705 A EC SP055705A EC SP055705 A ECSP055705 A EC SP055705A
Authority
EC
Ecuador
Prior art keywords
treatment
diabetes
type
activators
glicocinase
Prior art date
Application number
EC2005005705A
Other languages
English (en)
Inventor
Gregory Raymond Bebernitz
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP055705A publication Critical patent/ECSP055705A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/50—Nitrogen atoms bound to hetero atoms
    • C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Los compuestos de la fórmula (I) proporcionan agentes farmacológicos que son activadores de glucocinasa y de esta manera pueden ser empleados para el tratamiento de condiciones mediadas por glucocinasa. Por consiguiente, los compuestos de la fórmula (I) pueden ser empleados para la prevención y el tratamiento de tolerancia dañada de glucosa, diabetes de Tipo 2 y obesidad, en donde Q es la fórmula (II) o la fórmula (III), R es un radical de la fórmula (IV) o (V) o (VI), en donde R, R1-R6, R12 y R13 son como se definen en la descripción
EC2005005705A 2002-10-03 2005-03-28 (tiazol-2-il)-amida o sulfonamida substituida como activadores de glicocinasa utiles en el tratamiento de diabetes de tipo 2 ECSP055705A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41586002P 2002-10-03 2002-10-03

Publications (1)

Publication Number Publication Date
ECSP055705A true ECSP055705A (es) 2005-05-30

Family

ID=32469191

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2005005705A ECSP055705A (es) 2002-10-03 2005-03-28 (tiazol-2-il)-amida o sulfonamida substituida como activadores de glicocinasa utiles en el tratamiento de diabetes de tipo 2

Country Status (18)

Country Link
US (2) US7812167B2 (es)
EP (1) EP1549626A1 (es)
JP (1) JP2006509774A (es)
KR (1) KR20050074959A (es)
CN (2) CN101805358A (es)
AU (1) AU2003302279B2 (es)
BR (1) BR0314864A (es)
CA (1) CA2498089A1 (es)
CO (1) CO5721000A2 (es)
EC (1) ECSP055705A (es)
HK (1) HK1079788A1 (es)
MX (1) MXPA05003559A (es)
NO (1) NO20052159L (es)
NZ (1) NZ539013A (es)
PL (1) PL375021A1 (es)
RU (1) RU2005113713A (es)
WO (1) WO2004050645A1 (es)
ZA (1) ZA200501532B (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
PL375021A1 (en) 2002-10-03 2005-11-14 Novartis Ag Substituted (thiazol-2-yl) -amide or sulfonamide as glycokinase activators useful in the treatment of type 2 diabetes
GB0226930D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
PL378117A1 (pl) 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
NZ544784A (en) * 2003-07-28 2009-11-27 Reddys Lab Inc Dr Treatment and prevention of cardiovascular events using a beta-adrenergic receptor antagonist, a diuretic, an inhibitor of HMG CoA reductase, an inhibitor of the rennin-angiotensin system and asprin; wherein acidic and basic components are separated.
JP2007530631A (ja) 2004-04-02 2007-11-01 ノバルティス アクチエンゲゼルシャフト チアゾロピリジン誘導体、それを含む医薬組成物およびグルコキナーゼ介在性状態の処置法
BRPI0509573A (pt) * 2004-04-02 2007-09-25 Novartis Ag derivados de sulfonamida-tiazolpiridina como ativadores de glicocinase úteis para o tratamento de diabetes do tipo 2
KR20080105180A (ko) * 2004-08-12 2008-12-03 프로시디온 리미티드 치환된 페닐아세트아미드 및 글루코키나제 활성화제로서의 그의 용도
CN101203244A (zh) * 2005-07-01 2008-06-18 诺瓦提斯公司 肾素抑制剂和胰岛素分泌促进剂或胰岛素敏化剂的组合产品
KR20080040046A (ko) 2005-08-31 2008-05-07 아스텔라스세이야쿠 가부시키가이샤 티아졸 유도체
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
GT200600429A (es) * 2005-09-30 2007-04-30 Compuestos organicos
GT200600428A (es) * 2005-09-30 2007-05-21 Compuestos organicos
US20090005391A1 (en) * 2005-11-03 2009-01-01 Matthew Colin Thor Fyfe Tricyclo Substituted Amides
US20070116756A1 (en) * 2005-11-23 2007-05-24 Dr. Reddy's Laboratories Limited Stable pharmaceutical compositions
ES2378704T3 (es) * 2006-01-27 2012-04-17 Array Biopharma, Inc. Activadores de la glucocinasa
EP2001875A2 (en) 2006-03-08 2008-12-17 Takeda San Diego, Inc. Glucokinase activators
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
ATE522518T1 (de) 2006-05-31 2011-09-15 Takeda San Diego Inc Indazol- und isoindolderivate als glucokinaseaktivierende stoffe
AU2007278261A1 (en) 2006-07-24 2008-01-31 F. Hoffmann-La Roche Ag Pyrazoles as glucokinase activators
WO2008079787A2 (en) 2006-12-20 2008-07-03 Takeda San Diego, Inc. Glucokinase activators
TW200831081A (en) * 2006-12-25 2008-08-01 Kyorin Seiyaku Kk Glucokinase activator
WO2008084872A1 (ja) 2007-01-10 2008-07-17 Mitsubishi Tanabe Pharma Corporation ヒドラゾン誘導体
MX2009009525A (es) * 2007-03-07 2009-09-16 Kyorin Seiyaku Kk Activador de glucocinasa.
US8173645B2 (en) 2007-03-21 2012-05-08 Takeda San Diego, Inc. Glucokinase activators
CA2699718C (en) 2007-09-21 2014-05-27 Array Biopharma Inc. Pyridin-2-yl-amino-1, 2, 4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus
BRPI0906888A2 (pt) 2008-01-18 2015-11-03 Astellas Pharma Inc derivado de fenilacetamida
US8258134B2 (en) 2008-04-16 2012-09-04 Hoffmann-La Roche Inc. Pyridazinone glucokinase activators
US7741327B2 (en) 2008-04-16 2010-06-22 Hoffmann-La Roche Inc. Pyrrolidinone glucokinase activators
ME02198B (me) * 2008-04-28 2016-02-20 Kyorin Seiyaku Kk Derivati ciklopentilakrilamida
AU2009246167B2 (en) 2008-05-16 2013-08-22 Takeda California, Inc. Glucokinase activators
EP2348857B1 (en) 2008-10-22 2016-02-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
CA2741672A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US8222416B2 (en) 2009-12-14 2012-07-17 Hoffmann-La Roche Inc. Azaindole glucokinase activators
JP2013520502A (ja) 2010-02-25 2013-06-06 メルク・シャープ・エンド・ドーム・コーポレイション 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
CN102241644B (zh) * 2010-05-10 2013-07-17 天津药物研究院 α-氨基-3-芳基丙酰胺基噻唑衍生物、其制备方法和用途
MX348131B (es) 2011-02-25 2017-05-26 Merck Sharp & Dohme Novedosos derivados de azabencimidazol ciclico utiles como agentes antidiabeticos.
JP2014510145A (ja) * 2011-04-05 2014-04-24 アムジエン・インコーポレーテツド グルコキナーゼ調節タンパク質と相互作用する糖尿病治療用ベンゾジオキセピンおよびベンゾジオキシン化合物
US8921576B2 (en) 2011-10-19 2014-12-30 Kowa Company, Ltd. Spiroindoline compound, and medicinal agent comprising same
MX2015001500A (es) 2012-08-02 2015-04-08 Merck Sharp & Dohme Compuestos antidiabeticos triciclicos.
AU2014219020A1 (en) 2013-02-22 2015-07-23 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
US9650375B2 (en) 2013-03-14 2017-05-16 Merck Sharp & Dohme Corp. Indole derivatives useful as anti-diabetic agents
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
EP3551176A4 (en) 2016-12-06 2020-06-24 Merck Sharp & Dohme Corp. ANTIDIABETIC HETEROCYCLIC COMPOUNDS
US10968232B2 (en) 2016-12-20 2021-04-06 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6040321A (en) * 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
GB9823871D0 (en) * 1998-10-30 1998-12-23 Pharmacia & Upjohn Spa 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents
AU767830B2 (en) * 1999-03-29 2003-11-27 F. Hoffmann-La Roche Ag Glucokinase activators
US6610846B1 (en) 1999-03-29 2003-08-26 Hoffman-La Roche Inc. Heteroaromatic glucokinase activators
RU2242469C2 (ru) * 1999-03-29 2004-12-20 Ф.Хоффманн-Ля Рош Аг Активаторы глюкокиназы
US6320050B1 (en) 1999-03-29 2001-11-20 Hoffmann-La Roche Inc. Heteroaromatic glucokinase activators
US6353111B1 (en) * 1999-12-15 2002-03-05 Hoffmann-La Roche Inc. Trans olefinic glucokinase activators
ES2233660T3 (es) * 2000-05-03 2005-06-16 F. Hoffmann-La Roche Ag Activadores de glucokinasa alquinil fenil heteroaromaticos.
ATE304011T1 (de) 2000-05-03 2005-09-15 Hoffmann La Roche Hydantoin-enthaltende glucokinase aktivatoren
ES2230309T3 (es) * 2000-05-08 2005-05-01 F. Hoffmann-La Roche Ag Fenilacetamidas sustituidas y su empleo con ativadores de qucokinasa.
DK1283830T3 (da) * 2000-05-08 2008-08-25 Hoffmann La Roche Para-amin-substituerede phenylamidglucokinase-aktivatorer
US6489485B2 (en) 2000-05-08 2002-12-03 Hoffmann-La Roche Inc. Para-amine substituted phenylamide glucokinase activators
JP2001333778A (ja) * 2000-05-26 2001-12-04 Akihiko Shiraishi グルコキナーゼ活性化物質、糖尿病治療薬及び抗肥満薬
EP1305301B1 (en) * 2000-07-20 2005-06-15 F. Hoffmann-La Roche Ag Alpha-acyl and alpha-heteroatom-substituted benzene acetamide glucokinase activators
JP2002053566A (ja) * 2000-08-11 2002-02-19 Japan Tobacco Inc チアゾール化合物及びその医薬用途
US6369232B1 (en) 2000-08-15 2002-04-09 Hoffmann-La Roche Inc. Tetrazolyl-phenyl acetamide glucokinase activators
US6433188B1 (en) 2000-12-06 2002-08-13 Wendy Lea Corbett Fused heteroaromatic glucokinase activators
DE60117059T2 (de) * 2000-12-06 2006-10-26 F. Hoffmann-La Roche Ag Kondensierte heteroaromatische glucokinaseaktivatoren
US6482951B2 (en) 2000-12-13 2002-11-19 Hoffmann-La Roche Inc. Isoindolin-1-one glucokinase activators
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
JP2005526702A (ja) 2001-12-03 2005-09-08 ノボ　ノルディスク　アクティーゼルスカブ グルカゴンアンタゴニストとの組み合わせにおける２型糖尿病治療のためのグルコキナーゼ活性化剤の使用
US6911545B2 (en) 2001-12-19 2005-06-28 Hoffman-La Roche Inc. Crystals of glucokinase and methods of growing them
JP2005518391A (ja) * 2001-12-21 2005-06-23 ノボ　ノルディスク　アクティーゼルスカブ Ｇｋ活性化剤としてのアミド誘導体
AU2003221140B9 (en) 2002-03-26 2009-07-30 Banyu Pharmaceutical Co., Ltd. Novel aminobenzamide derivative
BR0309546A (pt) 2002-04-26 2005-02-15 Hoffmann La Roche Composto, composição farmacêutica que compreende o mesmo, processo para a sua preparação e utilização e método para tratamento profilático ou terapêutico de diabetes do tipo ii
US20070231874A1 (en) 2002-05-16 2007-10-04 Kenji Kamata Crystal of glucokinase protein, and method for drug design using the crystal
CA2744893A1 (en) 2002-06-27 2004-01-08 Novo Nordisk A/S Aryl carbonyl derivatives as glucokinase activators
PL375021A1 (en) 2002-10-03 2005-11-14 Novartis Ag Substituted (thiazol-2-yl) -amide or sulfonamide as glycokinase activators useful in the treatment of type 2 diabetes
ES2293005T3 (es) * 2002-10-03 2008-03-16 F. Hoffmann-La Roche Ag Indol-3-carboxamidas como activadores de la glucocinasa.
PE20040801A1 (es) 2002-12-12 2004-11-25 Hoffmann La Roche Derivados de pirazina y piridina 5-sustituidos como activadores de glucoquinasa
JP4716734B2 (ja) 2003-01-06 2011-07-06 イーライ リリー アンド カンパニー グルコキナーゼ活性化物質としての置換されたアリールシクロプロピルアセトアミド
AU2003294376A1 (en) 2003-01-06 2004-08-10 Eli Lilly And Company Heteroaryl compounds
WO2004072066A1 (en) 2003-02-11 2004-08-26 Prosidion Limited Tri(cyclo) substituted amide glucokinase activator compounds
PL378117A1 (pl) 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
BRPI0407283A (pt) 2003-02-13 2006-01-31 Banyu Pharma Co Ltd Composto, composição farmacêutica, e, agente ativador de glucoquinase, agentes terapêuticos e/ou agentes preventivos para diabetes melito e obesidade
RU2330030C2 (ru) 2003-02-26 2008-07-27 Баниу Фармасьютикал Ко., Лтд. Производные гетероарилкарбамоилбензола
EP1532980A1 (en) 2003-11-24 2005-05-25 Novo Nordisk A/S N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes
JP2007530631A (ja) * 2004-04-02 2007-11-01 ノバルティス アクチエンゲゼルシャフト チアゾロピリジン誘導体、それを含む医薬組成物およびグルコキナーゼ介在性状態の処置法
BRPI0509573A (pt) 2004-04-02 2007-09-25 Novartis Ag derivados de sulfonamida-tiazolpiridina como ativadores de glicocinase úteis para o tratamento de diabetes do tipo 2
AU2005235798A1 (en) 2004-04-21 2005-11-03 Prosidion Limited Tri(cyclo) substituted amide compounds
KR20080105180A (ko) 2004-08-12 2008-12-03 프로시디온 리미티드 치환된 페닐아세트아미드 및 글루코키나제 활성화제로서의 그의 용도
BRPI0518798A2 (pt) 2004-12-03 2008-12-09 Transtech Pharma Inc composto, composiÇço farmacÊutica, e, mÉtodos para tratar diabete tipo ii e para tratar uma condiÇço ou distérbio
GT200600429A (es) 2005-09-30 2007-04-30 Compuestos organicos
GT200600428A (es) 2005-09-30 2007-05-21 Compuestos organicos

Also Published As

Publication number Publication date
PL375021A1 (en) 2005-11-14
US20100330021A1 (en) 2010-12-30
CN1703408A (zh) 2005-11-30
RU2005113713A (ru) 2006-01-20
KR20050074959A (ko) 2005-07-19
BR0314864A (pt) 2005-08-02
MXPA05003559A (es) 2005-06-03
AU2003302279A1 (en) 2004-06-23
CA2498089A1 (en) 2004-06-17
WO2004050645A1 (en) 2004-06-17
CN101805358A (zh) 2010-08-18
WO2004050645A8 (en) 2005-05-19
NZ539013A (en) 2007-05-31
HK1079788A1 (zh) 2006-04-13
US20050282851A1 (en) 2005-12-22
NO20052159L (no) 2005-05-02
CO5721000A2 (es) 2007-01-31
ZA200501532B (en) 2006-11-29
AU2003302279B2 (en) 2008-06-12
EP1549626A1 (en) 2005-07-06
US7812167B2 (en) 2010-10-12
JP2006509774A (ja) 2006-03-23

Similar Documents

Publication Publication Date Title
ECSP055705A (es) (tiazol-2-il)-amida o sulfonamida substituida como activadores de glicocinasa utiles en el tratamiento de diabetes de tipo 2
ECSP066894A (es) Derivados de sulfonamida-tiazolpiridina como activadores de glucocinasa utiles en el tratamiento de diabetes de tipo 2
PA8584001A1 (es) Indol-3-carboxamidas como activadores de glucoquinasa (gk)
UY28121A1 (es) Activadores de glucoquinasa heteroaromaticos de seis miembros 5-sustituidos
GT200300096A (es) Activadores de cicloalquil sustituidos y cicloalquil oxigenados de glucoquinasa
ECSP044935A (es) Inhibidores de la dipeptidil peptidasa beta-amino heterocíclica para el tratamiento o la prevención de la diabetes
UY27069A1 (es) Activadores de glucocinasa del tipo isoindolin-1-ona
ECSP099413A (es) COMPUESTOS A BASE DE 4 - fenil - 6 - (2,2,2 - trifluoro - 1 - feniletoxi)pirimidina Y MÉTODOS PARA SU EMPLEO
UY27511A1 (es) Nuevos agentes andidiabéticos
ECSP055851A (es) Derivados de indolil pirazinona utiles para el tratamiento de trastornos hiperproliferativos y enfermedades asociadas con la angiogenesis
BRPI0506662A (pt) composto
ECSP045474A (es) 1-(aminoalquil)-3-sulfonilazaindoles como ligandos de 5-hidroxitriptamina-6
SV1999000047A (es) Nuevas dihidropirimidinas fef. lea 32792-sv
PE20060561A1 (es) Compuestos derivados de hidantoina
GT200100243A (es) Activadores heteroaromaticos fusionados de la glucoquinasa
PE20040165A1 (es) Uso de analogos del benzimidazol en el tratamiento de la proliferacion celular
AR091405A2 (es) Omega-carboxiaril difenil urea sustituida con fluoro y composiciones farmaceuticas que las contienen
CR8402A (es) Indazol-o-glucosidos sustitutos
DE60315146D1 (de) Heteroarylsubstituierte biphenylderivate als inhibitoren von p38-kinase
GT200000198A (es) Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos.
ECSP055746A (es) Antagonistas de cgrp elegidos, procedimiento para su preparación, así como su empleo como medicamentos
BRPI0514630B8 (pt) compostos de alfa-mercaptoacetanilidas de s-triazolila e composições farmacêuticas
CR8350A (es) 4-anilino-3-quinolincarbonitrilos para el tratamiento de leucemia mielogenica cronica
AR029837A1 (es) Anilidas de acidos sulfonicos substituidas
ES2133416T3 (es) Ligandos de subtipos de receptores de dopamina.